Cardionovum

Be up
to date.

Latest press release

Dott. Ielasi (Milan, Italy) speaks to Radcliffe at EuroPCR 2023 congress held in Paris (France) about the results of the Hyper Study 2-years Follow-up.

 

In this video interview, Dott. Ielasi summarizes the benefits of RESTORE® paclitaxel eluting balloon and comments the results of the Hyper study at 2 years, putting a focus on the encouraging results of the combined use of modern DES and RESTORE® DEB in the context of de novo diffuse CAD: in detail, results showed a 2-year clinical follow-up available for the vast majority of the patients enrolled (n=105/106, 99%) and a low incidence of Device oriented Composite Endpoint (DoCE) equal to 4.6% at 24 months.

 

In conclusion, even if larger and more robust data from RCTs (vs. full metal jacket PCIs) are needed to confirm the findings, the HYPER study reports very encouraging results in terms of safety and efficacy of the hybrid approach in the treatment of diffuse CAD.

Prof. Matteo Tozzi (Varese, Italy) spoke to Vascular News at Charing Cross 2023 meeting held in London (England) about the variety of vascular access complications and their treatment options.

 

In this video-interview, Prof. Tozzi commented as fantastic the clinical outcomes of Aperto® DCB in his recent analysis, in which more than 600 Aperto® DCB have been used in ArteriousVenous Fistula (AVF) and AVG, including a large number of Central Vein Stenosis (CVS).

Prof. Michael Lichtenberg (Arnsberg, Germany) speaks to Vascular News at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2022 annual meeting in Barcelona (Spain) about the importance on new endovascular strategies, such as Drug-Coated Balloons (DCBs), to improve patency rates in patients with consecutive neointimal hyperplasia in haemodialysis access.

 

In this interview, a particular focus is put on the promising results of APERTO® OTW, our high-pressure paclitaxel releasing DCB, considered as “one of the very promising new technologies” for treating restenosis in dialysis access patients

Bonn, Germany. November 16, 2022 – Data presented at Innovation session today at the CSC 2022 congress demonstrated an equivalent performance of the Xlimus® DES in terms of OCT derived endpoints than the Synergy™ DES, including Neointimal Volume and Neointimal Volume weighted by length at 6 months. Secondary endpoints, including other OCT parameters, such as in-stent Minimum Lumen Area (MLA) and percentage of strut coverage as well as clinical endpoints, showed no significant differences between the two groups in any of the evaluated parameters within the Xlimit RCT.

Prof. Matteo Tozzi (Varese, Italy) speaks to Vascular News at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2022 annual meeting in Barcelona (Spain) about his new study that analyzes the concentrations of paclitaxel in the bloodstream after the use of a Drug-Coated Balloons (DCBs) in AVFs.

We are proud to announce that we have received the authorization by the Secretaria de Salud and COFEPRIS to distribute APERTO® OTW in Mexico.

Upcoming events

Cardionovum® at 39 Jahrestagung der Deutschen Gesellschaft fur Gefabchirurgie und Gefabmedizin (DGG)

Cardionovum® is pleased to invite you to visit us at booth #005

Location:

Osnabrück Halle
Schlosswall 1-9
49074 Osnabrück

Date: Sep 27, 2023–Sep 30, 2023

Cardionovum® at GISE 2023

Cardionovum® is pleased to invite you to visit us at booth #11

Location:

Allianz MiCo - Milano Congressi
South Wing
Viale Eginardo - Gate 2
20149 Milano, Italy

Date: Oct 03, 2023–Oct 06, 2023

Latest events

Cardionovum at Charing Cross

Cardionovum participates at Charing Cross

Date: Apr 25, 2016–Apr 28, 2016

Location: London, UK

Visit website >>

Cardionovum at LINC

Cardionovum participates at LINC Leipzig Interventional Course

Date: Jan 25, 2016–Jan 28, 2016

Location: Leipzig, Germany

Learn more >>

Visit website >>

go top